C

Caladrius Biosciences Inc
LSE:0HS8

Watchlist Manager
Caladrius Biosciences Inc
LSE:0HS8
Watchlist
Price: 1.955 USD -3.46% Market Closed
Market Cap: 37.9m USD

Caladrius Biosciences Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Caladrius Biosciences Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
C
Caladrius Biosciences Inc
LSE:0HS8
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Inventory
$4.9B
CAGR 3-Years
16%
CAGR 5-Years
7%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Inventory
$4.4B
CAGR 3-Years
44%
CAGR 5-Years
34%
CAGR 10-Years
8%
Amgen Inc
NASDAQ:AMGN
Inventory
$6.3B
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Inventory
$1.6B
CAGR 3-Years
61%
CAGR 5-Years
46%
CAGR 10-Years
42%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Inventory
$2.4B
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
29%
No Stocks Found

Caladrius Biosciences Inc
Glance View

Market Cap
37.9m USD
Industry
Biotechnology

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. The company is headquartered in Basking Ridge, New Jersey and currently employs 27 full-time employees. The firm is developing therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company’s product candidates include CLBS16, CLBS12 and CLBS201. The CLBS16 (XOWNA) is an experimental regenerative medicine that is being studied in a Phase IIb study (the FREEDOM trial) in the United States for the treatment of coronary microvascular dysfunction. The CLBS12 (HONEDRA) is an experimental regenerative medicine being studied in Japan for the prevention of serious adverse consequences of critical limb ischemia. The CLBS201 is an experimental regenerative medicine designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease.

0HS8 Intrinsic Value
4.012 USD
Undervaluation 51%
Intrinsic Value
Price
C

See Also

Back to Top